The Prevalence and Distribution of Vitreoretinal Interface Abnormalities among Urban Community Population in China
Table 5
The prevalence of VIAs within all subjects in this study (number of eyes or %).
Variables
Type 2 diabetes patients
Normal subjects
45–54 years
55–64 years
≥65 years
value
Total
45–54 years
55–64 years
≥65 years
value#
Total
value†
ERM
20 (10.52)
32 (14.81)
44 (21.78)
<0.01
96 (13.95)
12 (6.12)
20 (9.62)
21 (10.29)
0.28
53 (8.72)
<0.01
PTMH
1 (0.52)
2 (0.93)
3 (1.48)
0.62
6 (0.87)
1 (0.51)
—
2 (0.98)
—
3 (0.49)
0.31
FTMH
2 (1.05)
1 (0.46)
3 (1.48)
0.56
6 (0.87)
—
2 (0.86)
2 (0.98)
—
4 (0.66)
0.52
VMT
8 (4.21)
12 (5.56)
24 (11.88)
<0.01
44 (6.39)
6 (3.06)
7 (3.36)
12 (5.88)
0.29
25 (4.11)
0.02
MC/ME
6 (3.15)
11 (5.09)
22 (10.89)
<0.01
39 (5.66)
1 (0.51)
5 (24.04)
11 (5.39)
0.01
17 (2.79)
<0.01
PVD
15 (7.89)
35 (16.20)
47 (23.26)
<0.01
97 (14.09)
21 (10.71)
46 (22.12)
52 (25.49)
<0.01
119 (19.57)
0.09
VIAs
52 (27.37)
93 (43.06)
143 (70.79)
<0.01
288 (41.86)
41 (20.92)
80 (38.46)
100 (49.02)
<0.01
221 (36.35)
<0.01
Epiretinal membrane without schisis (ERM); macular cysts/macular edema (MC/ME); partial thickness macular hole (PTMH); full-thickness macular hole (FTMH); posterior vitreous detachment (PVD); vitreomacular traction syndrome (VMT). Difference analysis between three age groups in Type 2 diabetes patients. #Difference analysis between three age-groups in normal subjects. †Difference analysis between Type 2 diabetes patients and normal subjects groups.
